FSS logo.png
Frontier Science Scotland Strengthens Board of Trustees with New Appointment
June 17, 2024 04:00 ET | Frontier Science Scotland
KINCRAIG, Scotland, June 17, 2024 (GLOBE NEWSWIRE) -- Frontier Science Scotland (FSS), a leading contract clinical research organisation, advancing drug development by delivering excellence in...
CenExel Highlights H
CenExel Highlights High Level of Psychometric Rater Stress and Burnout
May 29, 2024 13:00 ET | CenExel Clinical Research
Salt Lake City, Utah, May 29, 2024 (GLOBE NEWSWIRE) -- Poster presented today at American Society of Clinical Pharmacology (ASCP) Annual Meeting in Miami Beach, Florida, shows: High levels of...
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
October 30, 2023 09:07 ET | INmune Bio, Inc.
SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular...
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
October 06, 2023 07:50 ET | Purple Biotech Ltd.
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023 07:50 ET | Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab;  2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023 07:45 ET | SciSparc Ltd
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
LOGO roboto color with gray.png
Folia Health launches user-led research program, the Canopy Series
May 23, 2023 10:09 ET | Folia Health
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Today, Folia Health announced a first-of-its-kind observational research initiative driven by the priorities of patient and caregiver users. This program,...
Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients
May 17, 2023 08:00 ET | Sensus Healthcare, Inc.
BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment,...
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
May 02, 2023 07:25 ET | SciSparc Ltd
The Company previously announced positive interim results from the trial meeting its primary endpoints TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
Coya Therapeutics White Background.jpg
Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)
September 01, 2022 09:27 ET | Coya Therapeutics, Inc.
Phase 2a publication entitled “Combined Regulatory T-Lymphocyte and IL-2 Treatment is Safe, Tolerable, and Biologically Active for One Year in Persons with Amyotrophic Lateral Sclerosis” has been...